TESTICULAR FUNCTION FOLLOWING CYCLOPHOSPHAMIDE TREATMENT FOR CHILDHOOD NEPHROTIC SYNDROME - LONG-TERM FOLLOW-UP-STUDY

被引：21

作者：

BOGDANOVIC, R

BANICEVIC, M

CVORIC, A

机构：

[1] Institute for Mother and Child Health Care of Serbia, Belgrade, YU-11070

来源：

PEDIATRIC NEPHROLOGY | 1990年 / 4卷 / 05期

关键词：

TESTICULAR FUNCTION; CYCLOPHOSPHAMIDE; CHILDHOOD NEPHROTIC SYNDROME;

D O I：

10.1007/BF00869818

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Testicular function of 17 males treated in childhood or adolescence for nephrotic syndrome (NS) with cyclophosphamide (CY) for a mean time of 240 days (mean total dosage of 16.4 g or 641 mg/kg body weight) was evaluated at a mean time of 11.8 years after treatment. Five were azoospermic, 1 oligospermic, and 11 normospermic. There was a significant inverse correlation of sperm density with CY dosage and duration of treatment. All patients had undergone normal pubertal development and had normal sexual characteristics. Both basal and gonadotropin-releasing hormone-stimulated follicle-stimulating hormone (FSH) and luteinizing hormone (LH) concentrations were significantly raised in oligo- and azoospermic patients. Raised basal and peak FSH and LH concentrations in normospermic patients with a sperm count of less than 40 X 10(6)/ml were in keeping with impairment of two testicular components. However, mean basal plasma testosterone levels and mean peak plasma testosterone responses to human chorionic gonadotropin (HCG) did not differ significantly between patients and controls. Although LH responses to gonadotropin-releasing hormone suggested compensated Leydig cell failure in patients with testicular tubular damage, secretory reserve capacity of these cells, estimated by a HCG stimulation test, was preserved. Further follow-up is required to ascertain whether in these patients Leydig cell failure will develop with time.

引用

页码：451 / 454

页数：4

共 19 条

[1]

Coldbeck J.H., Experience with alkylating agents in the treatment of childhood nephrotic syndrome, Med J Aust, 1, pp. 987-989, (1963)

[2]

Barratt T.M., Soothill J.F., Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood, Lancet, 2, pp. 479-482, (1970)

[3]

Chiu J., McLaine P.N., Drummond K.N., A controlled prospective study of cyclophosphamide in relapsing, corticosteroid-responsive, minimal-lesion nephrotic syndrome in childhood, J Pediatr, 82, pp. 607-613, (1973)

[4]

Fairley K.F., Barrie J.U., Johnson W., Sterility and testicular atrophy related to cyclophosphamide therapy, Lancet, 1, pp. 568-569, (1972)

[5]

Rapola J., Koskimies O., Huttunen N.P., Floman P., Vilska J., Hallman N., Cyclophosphamide and the pubertal testis, Lancet, 1, pp. 98-99, (1973)

[6]

Penso J., Lippe B., Ehrlich R., Smith F.G., Testicular function in prepubertal and pubertal male patients treated with cyclophosphamide for nephrotic syndrome, J Pediatr, 84, pp. 831-836, (1974)

[7]

Etteldorf J.N., West C.D., Pitcock J.A., Willia D.L., Gonadal function, testicular histology, and meiosis following cyclophosphamide therapy in patients with nephrotic syndrome, J Pediatr, 88, pp. 206-212, (1976)

[8]

Lentz R.D., Bergstein J., Steffes M.W., Brown D.R., Prem K., Michael A.F., Vernier R.L., Postpubertal evaluation of gonadal function following cyclophosphamide therapy before and during puberty, J Pediatr, 91, pp. 385-394, (1977)

[9]

Hsu A.C., Folami A.O., Bain J., Rance C.P., Gonadal function in males treated with cyclophosphamide for nephrotic syndrome, Fertil Steril, 31, pp. 173-177, (1979)

[10]

Parra A., Santos D., Cervantes C., Sojo I., Carranco A., Cortes-Gallegos V., Plasma gonadotropins and gonadal steroids in children treated with cyclophosphamide, J Pediatr, 92, pp. 117-124, (1978)

← 1 2 →